BHVN
Price:
$9.61
Market Cap:
$1.02B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Industry
Biotechnology
IPO Date
2022-09-23
Stock Exchange
NYSE
Ticker
BHVN
According to Biohaven Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -1.28. This represents a change of -57.07% compared to the average of -2.98 of the last 4 quarters.
The mean historical PE Ratio of Biohaven Ltd. over the last ten years is -2.08. The current -1.28 PE Ratio has changed 6.04% with respect to the historical average. Over the past ten years (40 quarters), BHVN's PE Ratio was at its highest in in the December 2017 quarter at 0.66. The PE Ratio was at its lowest in in the September 2024 quarter at -7.35.
Average
-2.08
Median
-1.16
Minimum
-7.47
Maximum
0
Discovering the peaks and valleys of Biohaven Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = 0%
Minimum Annual PE Ratio = -7.47
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -4.03 | -46.08% |
| 2023 | -7.47 | 585.62% |
| 2022 | -1.09 | -10.97% |
| 2021 | -1.22 | -44.49% |
| 2020 | -2.20 | 229.21% |
| 2019 | -0.67 | -Infinity% |
| 2018 | 0 | 0% |
The current PE Ratio of Biohaven Ltd. (BHVN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.19
5-year avg
-3.20
10-year avg
-2.08
Biohaven Ltd.’s PE Ratio is greater than Intellia Therapeutics, Inc. (-2.41), greater than Immunome, Inc. (-8.23), greater than AbCellera Biologics Inc. (-6.35), greater than Vera Therapeutics, Inc. (-12.45), greater than Zenas BioPharma, Inc. (-9.02), greater than Celldex Therapeutics, Inc. (-9.85), greater than Pharvaris N.V. (-7.72), greater than Xeris Biopharma Holdings, Inc. (-32.76), greater than Sionna Therapeutics, Inc. (-30.60), greater than Immunocore Holdings plc (-71.72),
| Company | PE Ratio | Market cap |
|---|---|---|
| -2.41 | $1.02B | |
| -8.23 | $1.84B | |
| -6.35 | $1.09B | |
| -12.45 | $2.72B | |
| -9.02 | $1.60B | |
| -9.85 | $1.97B | |
| -7.72 | $1.80B | |
| -32.76 | $1.12B | |
| -30.60 | $1.82B | |
| -71.72 | $2.03B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biohaven Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biohaven Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Biohaven Ltd.'s PE Ratio?
How is the PE Ratio calculated for Biohaven Ltd. (BHVN)?
What is the highest PE Ratio for Biohaven Ltd. (BHVN)?
What is the 3-year average PE Ratio for Biohaven Ltd. (BHVN)?
What is the 5-year average PE Ratio for Biohaven Ltd. (BHVN)?
How does the current PE Ratio for Biohaven Ltd. (BHVN) compare to its historical average?